Author

Toan Van Le

Kanazawa University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Assay:multiome· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Iriya Fujitsuka· 2 shared Makie Ueda· 2 shared Rikinari HanayamaiD· 2 shared Shota ImaiiD· 2 shared Tomoyoshi YamanoiD· 2 shared Ayano Ikebuchi· 1 shared Hisamichi NaitoiD· 1 shared Hitoshi Sasatsuki· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Iriya Fujitsuka

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Modular mRNA platform for in vivo antigen-specific immune tolerance

Shota Imai, Naoto Nishida, Ryo Maeno, Ayano Ikebuchi, Hitoshi Sasatsuki, Risa Saito, Kazutaka Matoba, Sadahiro Iwabuchi, Tomohiro Iba, Hisamichi Naito, Kanto Nagamori, Toan Van Le, Iriya Fujitsuka, Makie Ueda, Rikinari Hanayama, Tomoyoshi Yamano

This paper introduces Tol-mRNA, a modular mRNA platform that induces antigen-specific immune tolerance by delivering PD-L1 and TGF-β along with antigen, showing therapeutic benefits in murine models and human immune settings.

bioRxiv · May 21, 2026 · PreprintImmunology

mRNA-Based Designer APCs Elicit Robust CD8⁺ and CD4⁺ T Cell Responses

Toan Van Le, Shota Imai, Iriya Fujitsuka, Makie Ueda, Sayuri Nakamae, Shusaku Mizukami, Rikinari Hanayama, Tomoyoshi Yamano

This paper develops an mRNA-based platform that reprograms somatic cells into designer APCs, enhancing T cell responses against tumors and demonstrating translational potential in human and mouse models.

bioRxiv · Sep 16, 2025 · PreprintImmunology